Artelo Biosciences (ARTL) Capital Expenditures (2017 - 2018)

Artelo Biosciences (ARTL) posted quarterly Capital Expenditures of -$42.0 for Q3 2018, down 310.0% quarter-over-quarter from $20.0 in Q1 2018.

Artelo Biosciences (ARTL) Capital Expenditures (2017 - 2018) Analysis & Trends

Artelo Biosciences (ARTL) has reported Capital Expenditures for 2 consecutive years, with -$42.0 the latest figure, recorded in Q3 2018.

In Q3 2018, Capital Expenditures changed N/A year-over-year to -$42.0; the TTM figure through May 2020 stood at -$42.0 (changed N/A YoY), while the FY2025 annual figure was -$188000.0, changed N/A from the prior year.
Capital Expenditures slipped to -$42.0 in Q3 2018 per ARTL's latest filing, from $20.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $867.0 in Q4 2017 and bottomed at -$42.0 in Q3 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	Artelo Biosciences	107,735.40	-492,264.60	-	-

Download Data